Abstract: TH-PO0460
Early Real-World Outcomes Among Patients (Pts) with IgAN Receiving Iptacopan: Analysis of the APPRISE-IgAN Data Platform
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Ndife, Briana C., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Trenz, Helen, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Moradi, Hamid, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Bose, Anirban, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Buchan, Claire, Asclepius Analytics, New York, New York, United States
- Buchan, Tayler, Asclepius Analytics, New York, New York, United States
- Baraka, Eugene, Asclepius Analytics, New York, New York, United States
- Canetta, Pietro A., Columbia University, New York, New York, United States
- Narayanan, Mohanram, Baylor Scott & White Health, Dallas, Texas, United States
Background
A Pt Platform for Real-world data on Iptacopan and Atrasentan in the United StatEs for pts with IgAN (APPRISE-IgAN) captures real-world data on US pts with IgAN prescribed iptacopan (complement factor B inhibitor) and/or atrasentan (endothelin type A receptor antagonist). We report clinical outcomes of pts on iptacopan enrolled to date.
Methods
Data from adults providing written electronic consent for enrollment from Oct 2024–Mar 2026 were sourced from specialty pharmacy and medical records. Duration of treatment was from date of iptacopan initiation (index) to discontinuation or data cutoff. Treatment adherence was assessed by ratio of days’ supply to days of follow-up (proportion of days covered, PDC). Outcomes for this analysis included change in urine protein-creatinine ratio from pre-index up to 6–9 months post-index and change in hematuria from pre-index up to 3–6 months post-index.
Results
Of 58 pts, median (interquartile range, IQR) age was 45.4 (36.9–55.4) years, 57% were male, and 84% had commercial insurance. Median (IQR) duration of iptacopan treatment was 8.2 (4.9–12.1) months; PDC was 94.7% (87.7%–98.1%). By data cutoff, 13 pts discontinued therapy. Of pts with clinical data (n=54), 63% and 59% had prior corticosteroid and delayed-release budesonide use, respectively. Of pts with complete Oxford MEST-C scores, 89% (25/28) had mesangial or endocapillary hypercellularity or crescents (M1, E1, or C1/C2). Proteinuria and hematuria values improved by 1–3 months and were sustained through 6–9 months and 3–6 months, respectively (Table 1).
Conclusion
In this real-world analysis, meaningful proteinuria and hematuria reduction in a population with IgAN was observed with iptacopan use, suggesting early clinical benefit. Ongoing data collection will provide more valuable information.
Acknowledgment
Medical writing support and editorial support were provided by Julia L. de Amorim, PhD (BOLDSCIENCE, Inc.), and were funded by Novartis Pharmaceuticals Corporation. This abstract was developed in accordance with Good Publication Practice (GPP) guidelines. The authors had full control of the content and made the final decision on all aspects of this publication.
Funding
- Commercial Support – Novartis Pharmaceuticals Corporation